Biosense To Fund Clinical Trial Of Atrial Fibrillation

Biosense has declared that it will be part of a public/private collaboration to fund a global clinical trial, to compare catheter ablation to medical therapy in treating atrial fibrillation (AFib).

Biosense joins the National Heart, Lung, and Blood Institute (NHLBI), a component of the National Institutes of Health, to fund the CABANA trial (Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation).

CABANA will also randomize approximately 3,000 patients over three years with half receiving catheter ablation, and the other half receiving medical therapy for heart rate or rhythm control.

Marcia Yaross, Vice President of Clinical, Regulatory and Health Policy at Biosense, said: “Biosense Webster is proud to be a substantial part of CABANA, a truly landmark trial that will provide important information to patients and physicians about treatment options for AFib, a significant risk factor for stroke and our investment in this study is part of our commitment to the principles of evidence-based medicine.”